{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P15692",
      "entity_text" : "VEGF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P15056",
      "entity_text" : "BRAF",
      "features" : [ {
        "to_base" : "A",
        "site" : 0,
        "feature_type" : "mutation",
        "evidence" : "mutant"
      } ],
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The former interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-beta) to reduce blood flow to the tumor for the treatment of patients with advanced renal cell carcinoma [XREF_BIBR], while the latter binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells [XREF_BIBR].",
  "reading_complete" : "2020-08-03T12:16:36Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T12:12:11Z",
  "trigger" : "prevents",
  "evidence" : [ "BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-beta) to reduce blood flow to the tumor for the treatment of patients with advanced renal cell carcinoma [ XREF_BIBR ], while the latter binds VEGF and prevents the interaction of VEGF" ],
  "pmc_id" : "3403482",
  "score" : 0
}